Literature DB >> 2419508

Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.

T Kato, B Dong, K Ishii, H Kinemuchi.   

Abstract

A dialysis cannula was implanted into rat striatum while the animals were anesthetized, and the area was perfused with Ringer solution while the animals were unanesthetized after at least 3 days following surgery. Concentrations of the metabolites of 3,4-dihydroxyphenylethylamine (DA) and 5-hydroxytryptamine (5-HT) in the perfusate were determined by HPLC with electrochemical detection. Levels of the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the perfusate significantly decreased after pargyline administration (50 mg/kg i.p.), which may inhibit not only monoamine oxidase (MAO)-B but also MAO-A in these high doses. The level of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) also decreased after pargyline treatment, although change in the relative level of 5-HIAA was less than that of DOPAC or HVA. To clarify the mechanisms for the metabolism of monoamines in rat striatum, highly specific MAO-A and -B inhibitors were used in the following experiments. Treatment with l-deprenyl (10 mg/kg), a specific inhibitor for MAO-B, did not cause any statistically significant change in DOPAC, HVA, and 5-HIAA levels. No significant change was found in rat striatal homogenates at 2 h after the same treatment with l-deprenyl. In contrast, low-dose treatment (1 mg/kg) with clorgyline, a specific inhibitor for MAO-A, caused a significant decrease in levels of these three metabolites in both the perfusates and tissue homogenates. In addition to the above three metabolites, the level of 3-methoxytyramine, which is an indicator of the amount of DA released, greatly increased after treatment with a low dose (1 mg/kg) of clorgyline.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2419508     DOI: 10.1111/j.1471-4159.1986.tb00650.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  29 in total

1.  Presynaptic dopaminergic function is largely unaltered in mesolimbic and mesostriatal terminals of adult rats that were prenatally exposed to cocaine.

Authors:  Paul E M Phillips; Josephine M Johns; Deborah A Lubin; Evgeny A Budygin; Raul R Gainetdinov; Jeffery A Lieberman; R Mark Wightman
Journal:  Brain Res       Date:  2003-01-24       Impact factor: 3.252

2.  Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.

Authors:  J Semba; M Doheny; P N Patsalos; G Sarna; G Curzon
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

Authors:  H K Wayment; J O Schenk; B A Sorg
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

4.  Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.

Authors:  Torun Malmlöf; Kristin Feltmann; Åsa Konradsson-Geuken; Frank Schneider; Rudolf-Giesbert Alken; Torgny H Svensson; Björn Schilström
Journal:  J Neural Transm (Vienna)       Date:  2014-06-07       Impact factor: 3.575

5.  Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment.

Authors:  Ravid Doron; Ziv Versano; Or Burstein; Motty Franko; Alon Shamir; Roni Toledano; Assaf Handelsman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2019-07-09       Impact factor: 3.444

6.  Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.

Authors:  P Celada; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

7.  In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.

Authors:  N Bel; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

8.  Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors:  M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

9.  The dopamine metabolite 3-methoxytyramine is a neuromodulator.

Authors:  Tatyana D Sotnikova; Jean-Martin Beaulieu; Stefano Espinoza; Bernard Masri; Xiaodong Zhang; Ali Salahpour; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

10.  Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study.

Authors:  N B Mercuri; A Bonci; A Siniscalchi; A Stefani; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.